United StatesÚltimas notícias

Evolution Metals & Technologies (NASDAQ:EMAT) reported Q2 2026 revenue of $1.6 million and a $0.1 million gross loss as it expanded its non-China rare earth magnet operations.

Zai Lab (NASDAQ:ZLAB) and argenx (NASDAQ:ARGX) reported that VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint with a 15.4-point TIS advantage over placebo at Week 52.

Centene (NYSE:CNC) named Chris Neczypor as its next CFO from January 1, 2027, while reaffirming 2026 adjusted diluted EPS guidance above $4.80.

Hareendra Dissabandara, Chairman at the Securities and Exchange Commission of Sri Lanka, says the government is "seriously working" on listing state-owned enterprises on the Colombo bourse. He speaks with Haslinda Amin on Insight with Haslinda Amin.

ArcelorMittal (NYSE:MT) said a missile strike hit its Kryvyi Rih steel operation in Ukraine, killing two people, injuring 13 and partially halting production.

HUTCHMED (NASDAQ:HCM) reported that ORPATHYS plus TAGRISSO significantly improved progression-free and overall survival versus platinum-based chemotherapy in its 338-patient Phase 3 SAFFRON trial.

Mesoblast (NASDAQ:MESO) completed treatment of 350 patients in its pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain caused by degenerative disc disease.

Endeavour Silver (NYSE:EXK) temporarily suspended operations at its Terronera silver-gold mine in Jalisco, Mexico, after a community blockade began on August 12.

Genco Shipping & Trading (NYSE:GNK) defended its $27.50-per-share cash framework after Diana Shipping (NYSE:DSX) withdrew its offer to acquire the remaining Genco shares.

argenx (NASDAQ:ARGX) reported that subcutaneous VYVGART Hytrulo met the Phase 3 ALKIVIA primary endpoint, producing a 15.4-point greater mean Total Improvement Score than placebo at Week 52.

HIVE Digital Technologies (NASDAQ:HIVE), through BUZZ High Performance Computing, signed a five-year GPU cloud services agreement worth approximately $350 million with an investment-grade enterprise customer.

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said Enhertu significantly improved progression-free survival versus standard first-line treatment for advanced HER2-mutant non-small cell lung cancer.